Design and synthesis of oxytocin glycosides for the treatment of pain and substance use disorder.

Peptide drugs are a promising alternative to classical small molecule therapeutics with diverse applications, ranging from antibiotic resistant infection to prostate cancer. Oxytocin (OT) is a highly evolutionarily conserved peptide neurohormone and has been of interest for pharmaceutical use since 1909. Despite their increased safety profile relative to most small molecule drugs, peptides are poor candidates based on the pharmacokinetic (PK) properties from their peptide nature. Broad application of OT as a drug has been limited by these same PK issues. Several strategies have been proposed to overcome these limitations, among them glycosylation, which was used in combination with other sequence modifications to produce robust antinociception in mouse models, increased selectivity and potency at the OT receptor, and improved stability in rats.

Structure-Based Design of Glycosylated Oxytocin Analogues with Improved Selectivity and Antinociceptive Activity.

Acute and chronic pain is often treated with opioids despite the negative side effects of constipation, physical dependence, respiratory depression, and overdose. The misuse of opioid analgesics has given rise to the opioid crisis/epidemic, and alternate nonaddictive analgesics are urgently needed. Oxytocin, a pituitary hormone, is an alternative to the small molecule treatments available and has been used as an analgesic as well as for the treatment and prevention of opioid use disorder (OUD). Clinical implementation is limited by its poor pharmacokinetic profile, a result of the labile disulfide bond between two cysteine residues in the native sequence. Stable brain penetrant oxytocin analogues have been synthesized by replacement of the disulfide bond with a stable lactam and glycosidation of the C-terminus. These analogues show exquisite selectivity for the oxytocin receptor and potent in vivo antinociception in mice following peripheral (i.v.) administration, supporting further study of their clinical potential.

Tunable carbocation-based redox active ambiphilic ligands: synthesis, coordination and characterization.

The synthesis of novel redox active ambiphilic ligands L1-L3 and their coordination chemistry to first-row late transition metal halides (M = Co and Ni) is reported. The heterocyclic carbocation scaffolds act as Lewis acid moieties while the pyridine anchor acts as the coordinating Lewis base. The high synthetic tunability of this ligand scaffold allows for control of its rigidity and electronic properties. Anion exchange and coordination of a chloride anion to the metal center was observed resulting in the formation of [MCl3]- metallate. Upon coordination to the pyridine anchor, the metallate centers adopt a canonical tetrahedral geometry, resulting in an overall neutral complex best described as a zwitterionic metallate trichloride bound to a cationic ligand. Characterization techniques including single crystal X-ray diffraction, cyclic voltammetry, and UV-Vis absorption spectroscopy were employed to better understand the structural and chemical properties of the ligands and metal complexes. A possible weak interaction between one of the chlorides and the carbenium moiety in the ligand is observed in crystals of both of the Co(ii) and Ni(ii) complexes with ligand L1. Density functional theory (DFT) calculations support that this electrostatic interaction for complexes 2a and 2b exists only in the solid state.